A biotech startup breaks a 3-year silence, displaying a $65M raise and a next-gen approach to PARP
Victoria Richon’s team at Ribon Therapeutics has been cruising under the biotech radar for the past 3 years. But with a $65 million B round to discuss with plans to move into the clinic, it’s time for a public display on just what they’ve been working on.
Over the past few years a whole group of players has been advancing PARPs into the market for cancer, throwing a monkey wrench in a mechanism cells use to repair damage. But while rivals stack up behind Lynparza from AstraZeneca and Merck, Ribon is taking it all one big step down the road.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
